Research programme: metabolic disorder therapeutics - Alnylam Pharmaceuticals
Alternative Names: Gene X based therapeutics-Alnylam PharmaceuticalsLatest Information Update: 16 Dec 2021
At a glance
- Originator Alnylam Pharmaceuticals
- Class Antihypoglycaemics; Cardiovascular therapies
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Metabolic disorders